Skip to content
Stay curious ↗

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Today/Drug Development
Drug Development · The big question

Biogen's Alzheimer's drug shows early promise in trials

STAT+: Pharmalittle: We’re reading about upbeat results for a Duchenne drug, Takeda layoffs, and much more

STAT News1 min readAI-assisted summary
Editorial illustration for STAT+: Pharmalittle: We’re reading about upbeat results for a Duchenne drug, Takeda layoffs, and much more
Editorial illustration

Summary

Alzheimer's disease research has a new development. Biogen has been testing an experimental drug called diranersen for patients in the early stages of the disease. This medication targets tau, a protein that builds up in the brains of Alzheimer's patients. In recent mid-stage clinical trials, known as Phase 2 testing, the drug successfully lowered the amount of tau in both the brain and spinal fluid of patients.

The most exciting part of this trial is that the drop in tau levels actually correlated with a slowdown in cognitive decline. In the past, scientists have created antibody treatments that clear tau, but they have struggled to prove that this clearance protects a patient's mind. However, the therapy is not without its hurdles. The drug yielded overall mixed results in this early testing phase, and it currently requires invasive administration through a spinal injection.

In separate industry news, Takeda Pharmaceutical is undergoing a major corporate restructuring. The company is preparing to launch several new drugs, which means their research and development expenses are climbing. To offset these rising costs and centralize their business functions, Takeda is planning significant job cuts.

Why it matters.

The Biogen trial offers a crucial glimmer of hope for the future of Alzheimer's care. For years, the medical industry has struggled to prove that clearing the tau protein translates into preserved memory and thinking skills. While still in early testing and requiring a difficult spinal injection, diranersen provides clinical evidence that targeting tau could meaningfully slow down cognitive decline. If these findings hold up in future studies, it could eventually lead to a vital new treatment path for patients facing the early stages of the disease.

Meanwhile, Takeda's restructuring highlights the intense financial pressure pharmaceutical companies face when bringing new medications to market. Balancing the high costs of research and development with the need to stay profitable often leads to tough operational choices, resulting in significant corporate layoffs even as companies prepare for new drug launches.

From the source

The story in numbers.

Clinical trial stage for Biogen's diranersen
Phase 2
Jobs to be cut by Takeda by FY 2026
4,500
Expected annual savings for Takeda by FY 2028
$1.27 billion
Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
Drug Development

A $122M boost for a fast, inside-the-body approach to cell therapy

Create Medicines recently secured $122 million to advance a new class of treatments for cancer and autoimmune diseases. They specialize in CAR-T cell therapy, a treatment that engineers the immune system to fight disease. But instead of the traditional method of removing cells from a patient to alter them in a lab, Create Medicines is developing therapies that work entirely inside the body, a process known as "in vivo" treatment. To achieve this, the therapy uses tiny fat bubbles called lipid nanoparticles to deliver messenger RNA, or mRNA, into the patient. Think of mRNA as a set of biological instructions. Once delivered, these instructions directly teach the patient's existing immune cells, including T cells, natural killer cells, and myeloid cells, to reprogram themselves into disease fighters. The startup has already dosed more than 50 patients, giving it the largest clinical dataset in the in vivo field. They recently began an early-stage clinical trial for an experimental therapy designed to attack solid tumors that carry a specific protein called HER2. Alongside this cancer research, the company is testing other treatments that target proteins called CD19 and BCMA to help patients with autoimmune conditions.

BioPharma Dive1 min read
Drug Development

Supreme Court Protects Access to Common Abortion Pill

The United States Supreme Court has decided to preserve access to mifepristone, a medication used in the most common method of abortion. By rejecting recent restrictions proposed by lower courts, the Supreme Court has ensured that patients can still obtain this widely used drug while an ongoing lawsuit continues to make its way through the legal system. Under this current legal order, patients do not need an in-person visit with a doctor to get the medication. Instead, they are permitted to continue receiving mifepristone directly from pharmacies or through the mail. This ruling maintains the existing distribution methods, meaning that access is expected to remain uninterrupted at least into the following year as further legal proceedings unfold.

STAT News1 min read
Drug Development

Living Implants: Engineered Bacteria Trapped in Gel Fight Infections

What if a medical implant could sense an infection and fight it off automatically? Researchers have created exactly that with a new technology called an "implantable living material." To build it, scientists used a specialized, water-based gel known as a polyvinyl alcohol hydrogel. This material acts as a tiny, flexible fortress. It is uniquely stiff and tough, designed to hold genetically engineered bacteria safely inside for up to six months without them escaping into the surrounding tissue. Inside this protective gel, the researchers trapped a modified version of E. coli bacteria to act as molecular guards. These engineered microbes are programmed to detect chemical signals given off by Pseudomonas aeruginosa, a dangerous pathogen that frequently causes infections around artificial joints. When the trapped bacteria sense the invader, they trigger a targeted self-destruct mechanism. This intentional cellular explosion releases a powerful antibacterial protein that easily passes through the microscopic pores of the gel to kill the infection outside. The research team tested this system in mice with artificial joint infections. Over a three-day treatment period, the living implant significantly reduced the amount of infectious bacteria compared to non-therapeutic controls. By keeping the helpful microbes physically contained while allowing their medicine to flow out, the researchers have found a clever way to turn living cells into localized drug factories.

GEN2 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗
Biogen's Alzheimer's drug shows early promise in trials — Daily Strand